Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways

The HER2-targeting antibody trastuzumab has shown effectiveness in treating HER2-positive breast and gastric cancers; however, its responses are limited. Currently, Nrf2 has been deemed as a key transcription factor in promoting cancer progression and resistance by crosstalk with other proliferative...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yun, Tian, Ziyin, Guo, Rui, Ren, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387975/
https://www.ncbi.nlm.nih.gov/pubmed/32765809
http://dx.doi.org/10.1155/2020/9867595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387975/
https://www.ncbi.nlm.nih.gov/pubmed/32765809
http://dx.doi.org/10.1155/2020/9867595

Ejemplares similares